Down-regulation of claudin-2 expression and proliferation by epigenetic inhibitors in human lung adenocarcinoma A549 cells

Journal of Biological Chemistry

Volumn 292, Issue 6, 2017, Pages 2411-2421

  Hichino, Asami ^a   Okamoto, Miki ^a   Taga, Saeko ^a   Akizuki, Risa ^a   Endo, Satoshi ^a   Matsunaga, Toshiyuki ^a   Ikari, Akira ^a  

^a GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATION; BIOLOGICAL ORGANS; CELL PROLIFERATION; CYTOLOGY; NUCLEIC ACIDS; PHOSPHORYLATION; RNA; SODIUM COMPOUNDS;

ADENOCARCINOMA CELLS; DOWN-REGULATION; ECTOPIC EXPRESSIONS; HDAC INHIBITORS; HISTONE DEACETYLASES; PHOSPHATIDYLINOSITOL 3-KINASE; PROMOTER REGION; SODIUM BUTYRATE;

CELLS;

AZACITIDINE; BUTYRIC ACID; CLAUDIN 2; HISTONE H3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MICRORNA; MICRORNA 497; PROTEIN KINASE B; TRICHOSTATIN A; UNCLASSIFIED DRUG; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; 3-(4-METHYLPHENYLSULFONYL)-2-PROPENENITRILE; CHROMONE DERIVATIVE; HYDROXAMIC ACID; MIRN497 MICRORNA, HUMAN; MORPHOLINE DERIVATIVE; NITRILE; SULFONE;

A-549 CELL LINE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BINDING SITE; CELL PROLIFERATION; CLAUDIN 2 GENE; CONTROLLED STUDY; DOWN REGULATION; DRUG DETERMINATION; DRUG EFFECT; GENE EXPRESSION; GENETIC STABILITY; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION; ADENOCARCINOMA; DRUG EFFECTS; GENETIC EPIGENESIS; GENETICS; LUNG TUMOR; METABOLISM; PATHOLOGY;

A549 CELLS; ADENOCARCINOMA; AZACITIDINE; BUTYRIC ACID; CELL PROLIFERATION; CHROMONES; CLAUDIN-2; DOWN-REGULATION; EPIGENESIS, GENETIC; HUMANS; HYDROXAMIC ACIDS; LUNG NEOPLASMS; MICRORNAS; MORPHOLINES; NITRILES; RNA, MESSENGER; SIGNAL TRANSDUCTION; SULFONES;

EID: 85012050354     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M116.762807     Document Type: Article

References (49)

1. Tsukita, S., Yamazaki, Y., Katsuno, T., Tamura, A., and Tsukita, S. (2008) Tight junction-based epithelial microenvironment and cell proliferation. Oncogene 27, 6930-6938
2. Powell, D. W. (1981) Barrier function of epithelia. Am. J. Physiol. 241, G275-G288
3. Matter, K., and Balda, M. S. (2003) Signalling to and from tight junctions. Nat. Rev. Mol. Cell Biol. 4, 225-236
4. Wittchen, E. S., Haskins, J., and Stevenson, B. R. (1999) Protein interactions at the tight junction. Actin has multiple binding partners, and ZO-1 forms independent complexes with ZO-2 and ZO-3. J. Biol. Chem. 274, 35179-35185
5. Furuse, M. (2010) Molecular basis of the core structure of tight junctions. Cold Spring Harb. Perspect. Biol. 2, a002907
6. Furuse, M., Fujita, K., Hiiragi, T., Fujimoto, K., and Tsukita, S. (1998) Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J. Cell Biol. 141, 1539-1550
7. Tsukita, S., Furuse, M., and Itoh, M. (2001) Multifunctional strands in tight junctions. Nat. Rev. Mol. Cell Biol. 2, 285-293
8. Mineta, K., Yamamoto, Y., Yamazaki, Y., Tanaka, H., Tada, Y., Saito, K., Tamura, A., Igarashi, M., Endo, T., Takeuchi, K., and Tsukita, S. (2011) Predicted expansion of the claudin multigene family. FEBS Lett. 585, 606-612
9. Turksen, K., and Troy, T. C. (2004) Barriers built on claudins. J. Cell Sci. 117, 2435-2447
10. Ikari, A., Sato, T., Watanabe, R., Yamazaki, Y., and Sugatani, J. (2012) Increase in claudin-2 expression by an EGFR/MEK/ERK/c-Fos pathway in lung adenocarcinoma A549 cells. Biochim. Biophys. Acta 1823, 1110-1118
11. Halász, J., Holczbauer, A., Páska, C., Kovács, M., Benyó, G., Verebély, T., Schaff, Z., and Kiss, A. (2006) Claudin-1 and claudin-2 differentiate fetal and embryonal components in human hepatoblastoma. Hum. Pathol. 37, 555-561
12. Kinugasa, T., Huo, Q., Higashi, D., Shibaguchi, H., Kuroki, M., Tanaka, T., Futami, K., Yamashita, Y., Hachimine, K., Maekawa, S., Nabeshima, K., Iwasaki, H., and Kuroki, M. (2007) Selective up-regulation of claudin-1 and claudin-2 in colorectal cancer. Anticancer Res. 27, 3729-3734
13. Xin, S., Huixin, C., Benchang, S., Aiping, B., Jinhui, W., Xiaoyan, L., Yu, W. B., and Minhu, C. (2007) Expression of Cdx2 and claudin-2 in the multistage tissue of gastric carcinogenesis. Oncology 73, 357-365
14. Ikari, A., Watanabe, R., Sato, T., Taga, S., Shimobaba, S., Yamaguchi, M., Yamazaki, Y., Endo, S., Matsunaga, T., and Sugatani, J. (2014) Nuclear distribution of claudin-2 increases cell proliferation in human lung adenocarcinoma cells. Biochim. Biophys. Acta 1843, 2079-2088
15. Ikari, A., Sato, T., Takiguchi, A., Atomi, K., Yamazaki, Y., and Sugatani, J. (2011) Claudin-2 knockdown decreases matrix metalloproteinase-9 activity and cell migration via suppression of nuclear Sp1 in A549 cells. Life Sci. 88, 628-633
16. Dhawan, P., Ahmad, R., Chaturvedi, R., Smith, J. J., Midha, R., Mittal, M. K., Krishnan, M., Chen, X., Eschrich, S., Yeatman, T. J., Harris, R. C., Washington, M. K., Wilson, K. T., Beauchamp, R. D., and Singh, A. B. (2011) Claudin-2 expression increases tumorigenicity of colon cancer cells: role of epidermal growth factor receptor activation. Oncogene 30, 3234-3247
17. Tabariès, S., Dong, Z., Annis, M. G., Omeroglu, A., Pepin, F., Ouellet, V., Russo, C., Hassanain, M., Metrakos, P., Diaz, Z., Basik, M., Bertos, N., Park, M., Guettier, C., Adam, R., Hallett, M., and Siegel, P. M. (2011) Claudin-2 is selectively enriched in and promotes the formation of breast cancer liver metastases through engagement of integrin complexes. Oncogene 30, 1318-1328
18. Sonoki, H., Sato, T., Endo, S., Matsunaga, T., Yamaguchi, M., Yamazaki, Y., Sugatani, J., and Ikari, A. (2015) Quercetin decreases claudin-2 expression mediated by up-regulation of microRNA miR-16 in lung adenocarcinoma A549 cells. Nutrients 7, 4578-4592
19. Park, Y. J., Claus, R., Weichenhan, D., and Plass, C. (2011) Genome-wide epigenetic modifications in cancer. Prog. Drug Res. 67, 25-49
20. Ansari, J., Shackelford, R. E., and El-Osta, H. (2016) Epigenetics in non-small cell lung cancer: from basics to therapeutics. Transl. Lung Cancer Res. 5, 155-171
21. Berdasco, M., and Esteller, M. (2010) Aberrant epigenetic landscape in cancer: how cellular identity goes awry. Dev. Cell 19, 698-711
22. Hamm, C. A., and Costa, F. F. (2015) Epigenomes as therapeutic targets. Pharmacol. Ther. 151, 72-86
23. Zöchbauer-Müller, S., Fong, K. M., Virmani, A. K., Geradts, J., Gazdar, A. F., and Minna, J. D. (2001) Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res. 61, 249-255
24. Weichert, W. (2009) HDAC expression and clinical prognosis in human malignancies. Cancer Lett. 280, 168-176
25. Valente, S., Trisciuoglio, D., Tardugno, M., Benedetti, R., Labella, D., Secci, D., Mercurio, C., Boggio, R., Tomassi, S., Di Maro, S., Novellino, E., Altucci, L., Del Bufalo, D., Mai, A., and Cosconati, S. (2013) tert-Butylcarbamate-containing histone deacetylase inhibitors: apoptosis induction, cytodifferentiation, and antiproliferative activities in cancer cells. ChemMedChem 8, 800-811
26. Valente, S., Trisciuoglio, D., De Luca, T., Nebbioso, A., Labella, D., Lenoci, A., Bigogno, C., Dondio, G., Miceli, M., Brosch, G., Del Bufalo, D., Altucci, L., and Mai, A. (2014) 1,3,4-Oxadiazole-containing histone deacetylase inhibitors: anticancer activities in cancer cells. J. Med. Chem. 57, 6259-6265
27. Nakayama, F., Semba, S., Usami, Y., Chiba, H., Sawada, N., and Yokozaki, H. (2008) Hypermethylation-modulated downregulation of claudin-7 expression promotes the progression of colorectal carcinoma. Pathobiology 75, 177-185
28. Agarwal, R., Mori, Y., Cheng, Y., Jin, Z., Olaru, A. V., Hamilton, J. P., David, S., Selaru, F. M., Yang, J., Abraham, J. M., Montgomery, E., Morin, P. J., and Meltzer, S. J. (2009) Silencing of claudin-11 is associated with increased invasiveness of gastric cancer cells. PLoS ONE 4, e8002
29. Di Cello, F., Cope, L., Li, H., Jeschke, J., Wang, W., Baylin, S. B., and Zahnow, C. A. (2013) Methylation of the claudin 1 promoter is associated with loss of expression in estrogen receptor positive breast cancer. PLoS ONE 8, e68630
30. Memmott, R. M., and Dennis, P. A. (2009) Akt-dependent and -independent mechanisms of mTOR regulation in cancer. Cell. Signal. 21, 656-664
31. Schnermann, J., Huang, Y., and Mizel, D. (2013) Fluid reabsorption in proximal convoluted tubules of mice with gene deletions of claudin-2 and/or aquaporin1. Am. J. Physiol. Renal Physiol. 305, F1352-1364
32. + flow and nutrient transport in gut and leads to death from malnutrition. Gastroenterology 144, 369-380
33. Patonai, A., Erdélyi-Belle, B., Korompay, A., Somorácz, A., Straub, B. K., Schirmacher, P., Kovalszky, I., Lotz, G., Kiss, A., and Schaff, Z. (2011) Claudins and tricellulin in fibrolamellar hepatocellular carcinoma. Virchows Arch. 458, 679-688
34. Song, X., Li, X., Tang, Y., Chen, H., Wong, B., Wang, J., and Chen, M. (2008) Expression of claudin-2 in the multistage process of gastric carcinogenesis. Histol. Histopathol. 23, 673-682
35. Flores, A. R., Rêma, A., Carvalho, F., Faustino, A., and Dias Pereira, P. (2014) Reduced expression of claudin-2 is associated with high histological grade and metastasis of feline mammary carcinomas. J. Comp. Pathol. 150, 169-174
36. Kim, H. S., Kim, G. Y., Lim, S. J., and Kim, Y. W. (2012) Expression of the mammalian target of rapamycin pathway markers in lung adenocarcinoma and squamous cell carcinoma. Pathobiology 79, 84-93
37. Tang, X., Liu, D., Shishodia, S., Ozburn, N., Behrens, C., Lee, J. J., Hong, W. K., Aggarwal, B. B., and Wistuba, I. I. (2006) Nuclear factor-κB (NF-κB) is frequently expressed in lung cancer and preneoplastic lesions. Cancer 107, 2637-2646
38. Meylan, E., Dooley, A. L., Feldser, D. M., Shen, L., Turk, E., Ouyang, C., and Jacks, T. (2009) Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma. Nature 462, 104-107
39. Phuong, N. T., Kim, S. K., Lim, S. C., Kim, H. S., Kim, T. H., Lee, K. Y., Ahn, S. G., Yoon, J. H., and Kang, K. W. (2011) Role of PTEN promoter methylation in tamoxifen-resistant breast cancer cells. Breast Cancer Res. Treat. 130, 73-83
40. Van Den Broeck, A., Brambilla, E., Moro-Sibilot, D., Lantuejoul, S., Brambilla, C., Eymin, B., Khochbin, S., and Gazzeri, S. (2008) Loss of histone H4K20 trimethylation occurs in preneoplasia and influences prognosis of non-small cell lung cancer. Clin. Cancer Res. 14, 7237-7245
41. Barlési, F., Giaccone, G., Gallegos-Ruiz, M. I., Loundou, A., Span, S. W., Lefesvre, P., Kruyt, F. A., and Rodriguez, J. A. (2007) Global histone modifications predict prognosis of resected non small-cell lung cancer. J. Clin. Oncol. 25, 4358-4364
42. Buurman, R., Gürlevik, E., Schäffer, V., Eilers, M., Sandbothe, M., Kreipe, H., Wilkens, L., Schlegelberger, B., Kühnel, F., and Skawran, B. (2012) Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells. Gastroenterology 143, 811-820
43. Sampath, D., Liu, C., Vasan, K., Sulda, M., Puduvalli, V. K., Wierda, W. G., and Keating, M. J. (2012) Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia. Blood 119, 1162-1172
44. Yang, G., Xiong, G., Cao, Z., Zheng, S., You, L., Zhang, T., and Zhao, Y. (2016) miR-497 expression, function and clinical application in cancer. Oncotarget 7, 55900-55911
45. Zhao, W. Y., Wang, Y., An, Z. J., Shi, C. G., Zhu, G. A., Wang, B., Lu, M. Y., Pan, C. K., and Chen, P. (2013) Downregulation of miR-497 promotes tumor growth and angiogenesis by targeting HDGF in non-small cell lung cancer. Biochem. Biophys. Res. Commun. 435, 466-471
46. Li, D., Zhao, Y., Liu, C., Chen, X., Qi, Y., Jiang, Y., Zou, C., Zhang, X., Liu, S., Wang, X., Zhao, D., Sun, Q., Zeng, Z., Dress, A., Lin, M. C., et al. (2011) Analysis of MiR-195 and MiR-497 expression, regulation and role in breast cancer. Clin. Cancer Res. 17, 1722-1730
47. Guo, J., Miao, Y., Xiao, B., Huan, R., Jiang, Z., Meng, D., and Wang, Y. (2009) Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues. J. Gastroenterol. Hepatol. 24, 652-657
48. Guo, S. T., Jiang, C. C., Wang, G. P., Li, Y. P., Wang, C. Y., Guo, X. Y., Yang, R. H., Feng, Y., Wang, F. H., Tseng, H. Y., Thorne, R. F., Jin, L., and Zhang, X. D. (2013) MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer. Oncogene 32, 1910-1920
49. Han, Z., Zhang, Y., Yang, Q., Liu, B., Wu, J., Zhang, Y., Yang, C., and Jiang, Y. (2015) miR-497 and miR-34a retard lung cancer growth by co-inhibiting cyclin E1 (CCNE1). Oncotarget 6, 13149-13163